Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5426098

Title:Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta
Inventors:Carlino, Joseph A.; San Leandro, CA, USA
Summary:Described herein are methods by which the use of transforming growth factor beta (TGF?) increases hematopoietic progenitor cells in peripheral blood. The invention relates to a process by which TGF? is used to increase the number of stem cells in a subject's peripheral blood such that the subject's blood is drawn and the stem cells are removed and readministered to the patient after undergoing myelosuppressive therapy. Further disclosed is an alternate method by which TGF? is administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed and later administered to a separate recipient subject after the recipient subject receives myelosuppressive therapy. Therapeutic application are directed toward the alleviation of side effects in patients undergoing myelosuppressive therapy such as chemotherapy or radiation therapy.
Abstract:TGF.beta. is used to increase the numbers of stem cells in a subject's peripheral blood. Then the subject's blood is drawn and the stem cells removed. After myelosuppressive therapy is administered to the subject, the stem cells are administered to the subject. An alternate method provides for TGF.beta. administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed; after a recipient subject receives myelosuppressive therapy, the stem cells are administered to the recipient subject.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5426098
Application Number:US1993000116253
Date Filed:02/09/1993
Date Published:20/06/1995
Assignee:Celtrix Pharmaceuticals, Inc., Santa Clara, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/23/2021